Adamas Pharmaceuticals, Inc.
(NASDAQ : ADMS)

( )
ADMS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
PTLAPortola Pharmaceuticals, Inc. 0.00%17.836.5%$162.99m
HZNPHorizon Therapeutics Plc 3.40%49.566.5%$137.49m
MYOKMyoKardia, Inc. 0.72%107.501.8%$136.24m
VRXValeant Pharmaceuticals International, Inc. -2.26%17.7714.1%$104.56m
CTLTCatalent, Inc. 0.37%78.592.3%$99.65m
AXSMAxsome Therapeutics, Inc. -2.48%80.901.9%$79.79m
UTHRUnited Therapeutics Corp. 0.32%117.5714.3%$76.94m
AMRNAmarin Corp. Plc -0.55%7.241.6%$69.65m
ICPTIntercept Pharmaceuticals, Inc. -12.19%80.5116.8%$59.84m
GWPHGW Pharmaceuticals Plc 1.33%126.926.2%$55.95m
JAZZJazz Pharmaceuticals Plc -1.14%109.592.4%$53.60m
PRGOPerrigo Co. Plc 0.00%54.336.8%$48.45m
ICLRICON plc 1.07%166.514.3%$45.86m
SAGESAGE Therapeutics, Inc. 2.53%38.948.6%$40.94m
MDGLMadrigal Pharmaceuticals, Inc. 5.33%125.710.3%$30.66m

Company Profile

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.